We're pleased to report our Q1 2024 results, including important advancement of our drug development efforts in substance use disorders. In January, the FDA accepted the Investigational New Drug application for PEX010, our botanical psilocybin drug candidate, for treatment of substance use disorders. We also completed exports of PEX010 to researchers around the world, including the first shipments of botanical psilocybin to Australia and Israel. https://lnkd.in/eM9GGaQi
Filament Health
Pharmaceutical Manufacturing
Vancouver, British Columbia 2,313 followers
Psychedelic Medicines Naturally Derived
About us
Filament Health believes that standardized, naturally-derived psychedelic medicines can improve the lives of millions of people suffering from treatable conditions. Our mission is to see them in the hands of everyone who needs them, as soon as possible. (OTCQB:FLHLF)(NEO: FH)(FSE:7QS)
- Website
-
http://filament.health
External link for Filament Health
- Industry
- Pharmaceutical Manufacturing
- Company size
- 11-50 employees
- Headquarters
- Vancouver, British Columbia
- Type
- Public Company
- Founded
- 2020
Locations
-
Primary
Get directions
550 Burrard St
2900
Vancouver, British Columbia V7X, CA
Employees at Filament Health
Updates
-
May is Mental Health Awareness Month. At Filament, we believe that psychedelics hold significant potential for the treatment of many mental health conditions. Internally, we’re researching the effects of our botanical psilocybin for opioid use disorder through a Filament-funded Phase 2 clinical trial at The University of British Columbia. We also supply our psilocybin to teams of researchers around the world who are studying its effects for a range of mental health conditions including depression, PTSD, and anxiety, among others. We’re hopeful that this research will provide meaningful solutions for people suffering from treatable conditions. For some mental health conditions, psilocybin can currently be accessed in Canada via the Special Access Program. To learn more visit the Health Canada website: https://lnkd.in/edcJcCRQ
-
-
Our CEO Benjamin Lightburn will be hosting an AMA with CEO.CA 🔺 at 9AM PT / 12PM ET tomorrow to discuss our latest news and developments. Submit questions for Ben and tune in via: https://ceo.ca/fh
FILAMENT HEALTH CORP. (FH.NEO) on CEO.CA
ceo.ca
-
We're pleased to report our 2023 year-end results including $2.1 million in revenue and Health Canada | Santé Canada approval of a Filament-sponsored Phase 2 clinical trial studying our botanical psilocybin for opioid use disorder at The University of British Columbia. https://lnkd.in/gmRHHWa5
Filament Health Reports Q4 And Year End 2023 Financial Results And Operational Highlights
filament.health
-
We're pleased to announce that Michael Messinger has been appointed to Filament's Board of Directors. Mike brings over 20 years' experience in finance roles with biotechnology companies, and an extensive understanding of clinical development across a variety of therapeutic areas. We have also announced the appointment of Steven Nguyen, CPA as our Interim Chief Financial Officer. Steven has experience in accounting, tax and financial reporting across multiple industries. https://lnkd.in/gWVVXSzG
Filament Health Announces Appointment Of Michael Messinger To Its Board Of Directors
filament.health
-
We're proud to supply our botanical psilocybin drug candidate for this important research by Leah Mayo, PhD and her team at the University of Calgary: https://lnkd.in/gYPcTmb3
Effectiveness of psychedelics on alcohol use disorder the focus of U of C study
calgary.ctvnews.ca
-
Since March 1st, we have shipped our botanical psilocybin drug candidate, PEX010, to four countries for clinical trials at leading research institutions including Johns Hopkins Medicine. PEX010 will be studied in Canada, the United States, Belgium, and Israel, for mental health indications such as cannabis use disorder, depression, anxiety, and alcohol use disorder. From CEO Benjamin Lightburn: “Filament Health is one of the largest - if not the largest - supplier of psilocybin globally. We are incredibly proud to facilitate potentially life-saving research around the world with our consistent production of standardized, GMP botanical psilocybin.” https://lnkd.in/gduXMr3M
Filament Health Announces Shipments Of Botanical Psilocybin To Four Countries For Clinical Investigation
filament.health
-
Could psilocybin offer a solution to the opioid crisis? We take a look in our latest blog post: https://lnkd.in/eVXJBUyE
Psychedelics & Substance Use Disorders: An Innovative Approach to a Growing Crisis
filament.health
-
Filament Health reposted this
2024 is set to be a watershed year for #Psychedelics. Alongside an influx in biotech investment in the UK, the wider industry has seen a number of significant milestones that are set to accelerate the sector, return confidence and advance innovations in #MentalHealth. Featuring Beckley Psytech, Filament Health, Lykos Therapeutics (formerly MAPS PBC), MindBio Therapeutics, Cybin Inc, MindMed and Negev Capital. Find out more. 👇
Psychedelics in 2024: a year for investment
https://psychedelichealth.co.uk
-
Benjamin Lightburn was featured in Tricycle Day's latest newsletter and spoke to Henry Winslow about our focus on botanical psychedelic medicines:
Henry: Filament’s focus on natural, botanical medicines sets you apart from other psychedelic drug development companies. What do those terms mean exactly, and how did you land there? Benjamin: The distinction between natural and botanical substances is meaningful, especially in the context of drug development. A “natural” product is simply derived from nature, such as psilocybin extracted from mushrooms. However, a “botanical” drug, as defined by the FDA, maintains all secondary compounds alongside the primary one. From the regulators' point of view, a botanical drug is considered safer for clinical trials. They know people consume magic mushrooms, so there’s some safety assurance there. Individual compounds, on the other hand, might have unknown effects in isolation. Our process at Filament Health involves cultivating mushrooms in-house, drying and milling them into powder, and then extracting them with solvents. We've developed a unique purification method that retains minor compounds while removing inactive elements, allowing us to standardize our final product—PEX010—to contain a precise dose of psilocybin in each capsule. This meticulous approach ensures our product is not just natural, but botanical. It preserves the mushroom's full compound spectrum. What sets PEX010 apart from synthetic alternatives—apart from its full-spectrum complexity—is that it comes from a specific genetic strain of mushrooms. We safeguard our product’s genetic source material as a trade secret. That’s why our botanical drug can’t be easily replicated and what gives us a competitive advantage.
-